Get the Stockscreener App
0.939
0.81%
0.0075
Pre-market:
.95
0.011
+1.17%
Cardiff Oncology Inc stock is traded at $0.939, with a volume of 436.77K.
It is up +0.81% in the last 24 hours and down -29.40% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$0.9315
Open:
$0.9472
24h Volume:
436.77K
Relative Volume:
0.96
Market Cap:
$73.05M
Revenue:
$525.00K
Net Income/Loss:
$-44.76M
P/E Ratio:
-1.4116
EPS:
-0.6652
Net Cash Flow:
$-37.46M
1W Performance:
-3.30%
1M Performance:
-29.40%
6M Performance:
-45.72%
1Y Performance:
-56.53%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.88
$0.9949
52-Week Range:
$0.7566
$3.31
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
0.939 | 73.05M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
524.52 | 132.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
245.81 | 98.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.67 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
890.05 | 55.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
386.46 | 43.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-12-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-03-26 | Downgrade | Craig Hallum | Buy → Hold |
| Jun-01-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-01-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
CRDF S-8 & SEC Filings - Yahoo Finance Australia
CRDF 8-K & SEC Filings - Yahoo Finance Australia
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance Singapore
Is Cardiff Oncology (NASDAQ:CRDF) Building a More Durable Market Story? - Kalkine Media
Verastem, Inc. (VSTM) stock price, news, quote and history - au.finance.yahoo.com
Cardiff Oncology (Nasdaq:CRDF)Stock Analysis - Simply Wall Street
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com Canada
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com UK
Cardiff Oncology settles dispute with NMS over onvansertib rights By Investing.com - Investing.com UK
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com India
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development SummitSlideshow - Seeking Alpha
Cardiff Oncology (CRDF) Slips to $1.02 as Biotech Stock Holds Above Key SupportNarrow Range Breakout - dars.gov.et
Cardiff Oncology Announces Upcoming Conference Participation for Mani Mohindru, Ph.D. - Quiver Quantitative
Cardiff Oncology to Participate in September 2026 Conferences - GlobeNewswire
Cardiff Oncology will take part in two September cancer conferences - Stock Titan
Cardiff Oncology Inc. (CRDF) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiff Oncology Inc. (CRDF) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cardiff Oncology (NASDAQ: CRDF) seeks share boost that may dilute holders - Stock Titan
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - tradingview.com
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsOverbought Signal Alerts - careplusvn.com
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsVolume Weighted Price - dars.gov.et
CRDF PRE 14A & SEC Filings - Yahoo Finance Australia
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com UK
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology: Q2 Earnings Snapshot - KTVB
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - finance.yahoo.com
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - stocktitan.net
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer |
Jul 14 '26 |
Buy |
1.46 |
34,364 |
50,000 |
59,067 |
| Mohindru Mani | Chief Executive Officer |
Jun 18 '26 |
Buy |
1.21 |
24,703 |
29,891 |
24,703 |
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
4.38%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):